These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 15200450

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK.
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [Abstract] [Full Text] [Related]

  • 3. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
    Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N, Bicarbonate/Lactate Study Group.
    Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
    [Abstract] [Full Text] [Related]

  • 4. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.
    Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmén J, Larsson R, Ingman B, Simonsen O, van Hamersvelt HW, Johansson AC, Hylander B, Mayr M, Nilsson PH, Andersson PO, De los Ríos T.
    Perit Dial Int; 2009 Apr; 29(6):647-55. PubMed ID: 19910566
    [Abstract] [Full Text] [Related]

  • 5. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
    Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A.
    Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
    [Abstract] [Full Text] [Related]

  • 6. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
    Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E.
    Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ.
    Cochrane Database Syst Rev; 2014 Mar 27; (3):CD007554. PubMed ID: 24671928
    [Abstract] [Full Text] [Related]

  • 11. Biocompatible dialysis fluids for peritoneal dialysis.
    Htay H, Johnson DW, Wiggins KJ, Badve SV, Craig JC, Strippoli GF, Cho Y.
    Cochrane Database Syst Rev; 2018 Oct 26; 10(10):CD007554. PubMed ID: 30362116
    [Abstract] [Full Text] [Related]

  • 12. The influence of bicarbonate/lactate-buffered PD fluids on N{ε}-(carboxyethyl)lysine and N{ε}-(carboxymethyl)lysine in peritoneal effluent.
    Cnossen TT, Gladziwa U, van de Kerkhof JJ, Schalkwijk CG, Scheijen J, van Amersfoort J, Moret K, Beerenhout CH, Kooman JP.
    Perit Dial Int; 2011 Oct 26; 31(2):189-93. PubMed ID: 20671103
    [Abstract] [Full Text] [Related]

  • 13. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
    Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH.
    Nephrol Dial Transplant; 2009 Sep 26; 24(9):2899-908. PubMed ID: 19258384
    [Abstract] [Full Text] [Related]

  • 14. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK, Ho YW, Ng F, Tang C, Chan TM.
    Am J Kidney Dis; 2012 Dec 26; 60(6):966-75. PubMed ID: 22835900
    [Abstract] [Full Text] [Related]

  • 15. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
    Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE, Edefonti A, Fischbach M, Haluany K, Misselwitz J, Kemper MJ, Rönnholm K, Wygoda S, Schaefer F, European Pediatric Peritoneal Dialysis Study Group.
    BMC Nephrol; 2004 Oct 14; 5():14. PubMed ID: 15485574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
    Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, Chan HW, Li CS, Wong SS, Ho YW, Cheuk A, Tong MK, Tang SC.
    Perit Dial Int; 2012 Oct 14; 32(3):280-91. PubMed ID: 22045098
    [Abstract] [Full Text] [Related]

  • 18. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
    Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R, behalf of the DIUREST Study Group.
    Nephrol Dial Transplant; 2010 Jul 14; 25(7):2288-96. PubMed ID: 20197284
    [Abstract] [Full Text] [Related]

  • 19. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
    Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS).
    Nephrol Dial Transplant; 2007 Jul 14; 22(7):2038-44. PubMed ID: 17420168
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.